TB-500 Research Overview
TB-500 Research Overview
Research-Only Notice & Compliance Boundary
This document is compiled strictly for educational and analytical reference purposes within laboratory, academic, and clinical research settings. The compounds discussed herein are supplied strictly as Research Use Only (RUO) chemicals and are not intended for human or veterinary consumption, diagnostic use, or therapeutic administration. Core Research does not provide dosing, reconstitution, or clinical administration guidelines.
Scientific Context and Research Background of TB-500
TB-500 is a synthetic research peptide derived from the highly conserved actin-sequestering domain of thymosin beta-4, representing one of the most structurally characterised repair-category peptides currently available to the pre-clinical research community. Laboratories investigating cellular migration, cytoskeletal dynamics, and tissue-level repair signalling have increasingly positioned TB-500 as a reference compound of considerable analytical value.
The significance of TB-500 as a research entity cannot be overstated when one considers the broader context in which it operates. Thymosin beta-4 (Tβ4), the endogenous 43-amino-acid polypeptide from which TB-500’s active fragment is derived, was first isolated from calf thymus tissue in the early 1980s and has since been identified in virtually every nucleated mammalian cell type examined. Its ubiquitous expression pattern alone signals a fundamental biological role — one that extends well beyond the immune-modulatory functions initially attributed to the thymosin family. Over the subsequent four decades, a substantial body of pre-clinical literature has accumulated around Tβ4 and its synthetic analogues, with TB-500 emerging as a particularly tractable research tool owing to its focused sequence identity and relative synthetic accessibility.
From a research classification standpoint, TB-500 sits firmly within the repair peptide category — a designation that reflects its proposed mechanistic involvement in processes such as actin polymerisation modulation, angiogenic signalling, and the upregulation of cell-surface receptors implicated in migratory behaviour. These properties have made it a compound of sustained interest across disciplines as varied as cardiovascular biology, dermatological research, ophthalmology, and musculoskeletal science. Investigators working with in-vitro wound-healing assays, endothelial tube formation models, and rodent injury paradigms have all employed TB-500 as either a primary intervention compound or a mechanistic comparator.
For research procurement purposes, TB-500 is catalogued under Core Research product identifier and is supplied in lyophilised form with accompanying Certificate of Analysis (CoA) documentation. The compound’s research-grade status, combined with its well-defined sequence and established physicochemical profile, makes it a reliable reference standard for laboratories requiring reproducible, analytically verified material. The sections that follow provide a structured characterisation of TB-500’s molecular identity, its pre-clinical evidence base, and the operational considerations that inform responsible research use of this compound.
Molecular Structure and Physicochemical Properties
TB-500 is a synthetic peptide corresponding to the amino acid sequence Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-NH₂, representing residues 17–23 and the broader actin-binding domain of the full-length thymosin beta-4 molecule. In the most commonly referenced research formulation, TB-500 is understood to encompass the tetrapeptide core motif Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), which has itself attracted independent investigative interest, alongside the flanking sequence that confers the compound’s characteristic actin-sequestering geometry.
The molecular formula of TB-500 is C₂₁₂H₃₅₀N₅₆O₇₈S, with a calculated molecular weight of approximately 4,963.5 Da (daltons). This places it firmly within the mid-range peptide molecular weight bracket — sufficiently large to adopt defined secondary structural elements, yet compact enough to be synthesised reliably via standard solid-phase peptide synthesis (SPPS) methodologies using Fmoc chemistry. The peptide chain comprises 43 amino acid residues in its full thymosin beta-4 homologous form, with the N-terminus acetylated and the C-terminus presented as a primary amide, both modifications contributing meaningfully to the compound’s proteolytic stability profile under physiological buffer conditions.
In terms of physical state, research-grade TB-500 is supplied as a white to off-white lyophilised powder. The lyophilisation process — conducted under controlled temperature and pressure conditions — removes residual solvent and moisture to yield a hygroscopic solid with a typical residual moisture content of less than 5% by Karl Fischer titration. This physical form confers significant advantages for long-term storage stability, with lyophilised material demonstrating acceptable integrity when maintained at −20°C under desiccated, light-protected conditions. Upon reconstitution in sterile aqueous vehicles such as bacteriostatic water or phosphate-buffered saline (PBS) at pH 7.4, TB-500 exhibits good solubility at research-relevant concentrations, typically yielding clear to slightly opalescent solutions.
The isoelectric point (pI) of TB-500 is calculated at approximately 5.65, reflecting the compound’s net negative charge at physiological pH — a property with implications for its electrostatic interactions with actin monomers and cell-surface heparan sulphate proteoglycans in experimental systems. The peptide contains a single methionine residue, which introduces a potential oxidation-sensitive site; researchers conducting long-term stability studies or working with oxidative assay conditions should account for this vulnerability in their experimental design. High-performance liquid chromatography (HPLC) purity assessments of research-grade material should ideally confirm ≥98% purity by peak area, with mass spectrometric confirmation of the correct molecular ion providing an additional orthogonal identity verification. Core Research’s CoA documentation for product addresses these analytical parameters directly, providing researchers with the traceability data required for rigorous experimental reporting.
Pre-Clinical Research and Mechanism of Action
The pre-clinical research landscape surrounding TB-500 is both broad and mechanistically nuanced, spanning in-vitro cellular assays, ex-vivo tissue preparations, and a range of rodent and larger animal injury models. The compound’s proposed mechanisms of action are multifactorial, and the published evidence — while predominantly pre-clinical in nature — provides a substantive framework for understanding the biological pathways that TB-500 and its parent molecule thymosin beta-4 are hypothesised to engage.
Actin Sequestration and Cytoskeletal Modulation: The most extensively characterised molecular function of TB-500’s parent sequence is the sequestration of G-actin (globular actin) monomers, thereby regulating the dynamic equilibrium between monomeric and filamentous actin (F-actin) within cells. By binding G-actin in a 1:1 stoichiometric ratio, thymosin beta-4 and its synthetic analogues modulate the availability of actin for polymerisation, influencing lamellipodia formation, cell polarity, and directed migration. This cytoskeletal regulatory function is of particular relevance to researchers investigating wound-healing models, where coordinated keratinocyte and fibroblast migration is a rate-limiting step in epithelial closure. In-vitro scratch assay data from multiple independent groups have measured gap closure in monolayer cultures of human dermal fibroblasts and corneal epithelial cells exposed to thymosin beta-4 fragment peptides, with the findings attributed in part to actin dynamics at the leading edge of migrating cells.
Angiogenic Signalling Pathways: Beyond its cytoskeletal role, TB-500 has been investigated in the context of angiogenesis — the formation of new blood vessels from pre-existing vasculature. Published pre-clinical data report endothelial cell migration and tube formation in Matrigel assays as measured endpoints for thymosin beta-4, with proposed involvement of integrin-linked kinase (ILK) signalling and downstream activation of the Akt/PKB survival pathway. A study published in the journal Peptides [1] examined the structural and functional determinants of thymosin beta-4’s angiogenic activity, providing molecular-level insight into how specific sequence elements within the peptide contribute to its pro-angiogenic profile. These findings are directly relevant to researchers designing vascular biology assays in which TB-500 is employed as a positive control or mechanistic probe.
Anti-Inflammatory and Cytoprotective Mechanisms: A further dimension of TB-500’s pre-clinical profile concerns the inflammatory endpoints reported in that literature. Experimental data from rodent models of acute tissue injury have suggested that thymosin beta-4 administration is associated with reduced expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, alongside upregulation of anti-apoptotic mediators. The molecular basis for these effects remains an active area of investigation, with NF-κB pathway modulation and direct interaction with inflammatory cell populations both proposed as contributing mechanisms. Research published in the European Journal of Pharmaceutics and Biopharmaceutics [2] addressed formulation and delivery considerations for thymosin beta-4 fragment peptides, including the formulation variables that determine compound exposure in pre-clinical models.
Cardiac and Neural Research Models: Some of the most compelling pre-clinical data surrounding thymosin beta-4 and its analogues have emerged from cardiovascular and neurological research contexts. Rodent models of myocardial infarction have measured cardiac function, infarct size and cardiomyocyte survival as endpoints following systemic or local administration of thymosin beta-4, with angiogenic, anti-apoptotic and stem cell-activating mechanisms proposed as contributors. In neural injury models, including spinal cord contusion and traumatic brain injury paradigms, studies of thymosin beta-4 fragment peptides have measured axonal outgrowth, glial scarring and functional recovery endpoints. These findings, while requiring replication and mechanistic validation across independent laboratories, underscore the breadth of biological contexts in which TB-500 serves as a relevant research tool.
Musculoskeletal and Connective Tissue Research: TB-500 has also been employed in pre-clinical models examining tendon, ligament, and skeletal muscle repair. In-vitro studies using primary tenocyte cultures have measured proliferation and collagen synthesis following exposure to thymosin beta-4 fragment, while rodent models of tendon transection have measured histological repair and biomechanical properties in exposed animals compared to vehicle controls. These observations have positioned TB-500 as a compound of interest for researchers working at the intersection of orthopaedic biology and peptide pharmacology, though it bears emphasis that all such findings remain strictly within the pre-clinical domain and do not constitute evidence of clinical efficacy or safety in human subjects.
Collectively, the pre-clinical evidence base for TB-500 spans a mechanistic literature covering cytoskeletal, angiogenic, anti-inflammatory, and cytoprotective axes. The quality and reproducibility of this evidence varies across studies, and researchers are encouraged to critically appraise primary literature — including the DOI-referenced publications [1][2] — when designing assays and interpreting results. The compound’s research utility
Comparative Analysis and Specifications
Understanding TB-500’s technical specifications in relation to established analytical benchmarks is essential for laboratories seeking to integrate this compound into rigorous pre-clinical programmes. The following table summarises four critical parameters that directly inform experimental design, quality assurance workflows, and inter-laboratory reproducibility. Each specification reflects the standards expected of research-grade material supplied with full CoA documentation, as provided by Core Research under product identifier .
Researchers are advised to request batch-specific CoA documentation prior to experimental use and to cross-reference HPLC chromatograms against mass spectrometric data as a dual-verification approach. Where inter-batch comparisons are planned — for example, in longitudinal studies or multi-site collaborative programmes — retention of reference aliquots from each batch at −80°C provides a valuable analytical anchor for retrospective quality assessment.
Regulatory Status and Safety Compliance
The procurement, storage, and experimental use of research-grade peptides such as TB-500 must be conducted within a robust governance framework that reflects both institutional obligations and the broader regulatory environment governing research chemicals in the United Kingdom and internationally.
Regulatory Compliance: TB-500 is classified as a Research Use Only (RUO) compound and is not licensed as a medicinal product by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Its supply and use are governed by institutional research ethics frameworks, COSHH (Control of Substances Hazardous to Health) regulations, and applicable local legislation. Laboratories must ensure that all procurement activities are conducted through authorised institutional channels, with appropriate purchase authorisation and material receipt documentation maintained in auditable records.
Professional Standards — GMC and HCPC Alignment: Where research programmes involve medically or healthcare-professionally qualified investigators, the standards set by the General Medical Council (GMC) and the Health and Care Professions Council (HCPC) apply in full. These standards require that research activities are conducted with scientific integrity, that conflicts of interest are declared, and that any findings are communicated accurately and without misrepresentation. Investigators must not extrapolate pre-clinical findings to clinical recommendations, and must clearly distinguish research observations from evidence-based clinical guidance in all communications.
Safeguarding — Adult and Child Populations: Research institutions handling peptide compounds must maintain safeguarding policies that prevent access by unauthorised individuals, including minors. Secure storage protocols, restricted laboratory access, and clear labelling of all research materials as “Not for Human Use” are minimum requirements. Any concern that research compounds may be accessed or used outside of authorised experimental contexts must be escalated immediately through institutional safeguarding and compliance channels.
Data Protection and Research Integrity: All experimental data generated using TB-500 must be managed in accordance with the UK General Data Protection Regulation (UK GDPR) where personal or participant-linked data are involved. Research records — including CoA documentation, batch records, and experimental protocols — should be retained for a minimum of ten years in accordance with good laboratory practice (GLP) principles. Secure, access-controlled data storage systems are required, with clear data ownership and sharing agreements in place for multi-institutional collaborations.
Incident Reporting: Any adverse events, near-misses, or suspected misuse of research compounds must be reported through the institution’s designated safety officer and, where applicable, to the relevant regulatory authority. Transparent incident reporting is a cornerstone of responsible research governance and contributes to the broader evidence base informing safe laboratory practice standards.
Research Questions and Technical Support
What is TB-500 and how does it differ from full-length thymosin beta-4?
TB-500 is a synthetic peptide derived from the actin-binding domain of thymosin beta-4 (residues 17–23 and flanking sequence). Unlike the full 43-residue endogenous protein, TB-500 offers greater synthetic accessibility and focused mechanistic activity. In practice, researchers find this specificity advantageous when isolating cytoskeletal effects from broader immunomodulatory signals.
What purity standard should researchers require when sourcing TB-500?
A minimum of ≥98% purity by reverse-phase HPLC, confirmed by mass spectrometric identity verification, is the accepted benchmark for pre-clinical research applications. Sub-98% material introduces sequence-related impurities that add variability to concentration–response curves and complicate inter-assay reproducibility.
How should TB-500 be stored to maintain research-grade integrity?
Lyophilised TB-500 should be stored at −20°C under desiccated, light-protected conditions. Reconstituted aliquots require −80°C storage and should be used within three months. Researchers who have implemented single-use aliquoting protocols report markedly reduced batch-to-batch activity variation compared to repeated freeze-thaw cycling of bulk reconstituted stock.
Is TB-500 approved for human or veterinary therapeutic use?
No. TB-500 is classified strictly as a Research Use Only (RUO) compound and holds no regulatory approval for human or veterinary therapeutic, diagnostic, or prophylactic application in any jurisdiction. Investigators regularly emphasise that this classification must be communicated clearly in all grant applications, ethics submissions, and published methods sections.
What analytical documentation should accompany a research-grade TB-500 purchase?
A comprehensive Certificate of Analysis (CoA) should include HPLC chromatogram, mass spectrum, residual moisture content, TFA counter-ion declaration, and batch number. Procurement teams at research institutions consistently identify CoA completeness as the single most important differentiator when evaluating supplier reliability for regulatory audit purposes.
Which pre-clinical research models have most commonly employed TB-500?
TB-500 has been employed across in-vitro scratch assays, endothelial tube formation models, rodent myocardial infarction paradigms, tendon transection models, and neural injury preparations. Researchers with multi-model experience note that the compound’s angiogenic and cytoskeletal effects are most consistently reproduced in endothelial and fibroblast cell systems.
Does TB-500 contain any oxidation-sensitive residues that could affect experimental outcomes?
Yes. TB-500 contains a single methionine residue susceptible to oxidation under peroxide-containing or prolonged aerobic conditions. This can alter the compound’s actin-binding geometry and reduce biological activity. Laboratories conducting oxidative stress assays or using hydrogen peroxide-based cell treatments should include methionine oxidation controls in their experimental design.
How does Core Research’s product support research traceability requirements?
Core Research supplies TB-500 with batch-specific CoA documentation encompassing HPLC, mass spectrometry, and moisture data, enabling full analytical traceability from procurement to experimental use. Research compliance officers report that this documentation package satisfies institutional audit requirements and supports methods transparency in peer-reviewed publication submissions.